Maria Dall'Era, MD

Director, Lupus Clinic
Rheumatologist

Dr. Maria Dall'Era is a rheumatologist who directs both the UCSF Lupus Clinic and the clinical trials center of the UCSF Department of Medicine.

In addition to caring for patients, Dall'Era has a special research interest in systemic lupus erythematosus (SLE). She participates in clinical trials of potential new treatments for generalized lupus and lupus nephritis, kidney inflammation caused by lupus. Through her research, she hopes to develop advanced therapies for patients suffering from SLE.

Dall'Era earned her medical degree at UCSF, where she also completed her internal medicine residency, serving as chief resident, and a fellowship in rheumatology.

Clinics

Lupus Program
1825 Fourth St., Sixth Floor
San Francisco, CA 94158
Phone: (415) 353-7337
Fax: (415) 353-2861

Conditions & Treatments

  • Autoimmune Hepatitis
  • Myasthenia Gravis
  • Neuromyelitis Optica (NMO)
  • Osteoarthritis

More about Maria Dall'Era

Education

UCSF School of Medicine 1997

Residencies

UCSF Medical Center, Internal Medicine 2000
UCSF Medical Center, Internal Medicine 2001

Fellowships

UCSF Medical Center, Rheumatology 2004

Selected Research and Publications

  1. Merrill JT, Manzi S, Aranow C, Askenase A, Bruce I, Chakravarty E, Chong B, Costenbader K, Dall'Era M, Ginzler E, Hanrahan L, Kalunian K, Merola J, Raymond S, Rovin B, Saxena A, Werth VP. Lupus community panel proposals for optimising clinical trials: 2018. Lupus Sci Med. 2018; 5(1):e000258.
  2. Dall'Era M, Cisternas MG, Snipes K, Herrinton LJ, Gordon C, Helmick CG. The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project. Arthritis Rheumatol. 2017 10; 69(10):1996-2005.
  3. Dall'Era M. Treatment of lupus nephritis: current paradigms and emerging strategies. Curr Opin Rheumatol. 2017 May; 29(3):241-247.
  4. Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione-Schreiber LG, Callahan S, Goldmuntz EA, Keyes-Elstein L, Oswald M, Gregersen PK, Diamond B. Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2015 Jul; 67(7):1848-57.
  5. Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med. 2015; 2(1):e000089.
  6. Dall'Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, Rovin BH, Mackay M. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015 May; 67(5):1305-13.
  7. Ashouri JF, Davis JL, Farkas A, Durack JC, Ramachandran R, Dall'Era M. A young woman with systemic lupus erythematosus and extensive mesenteric vasculitis involving small and medium vessels. Arthritis Care Res (Hoboken). 2012 Dec; 64(12):1928-33.
  8. Dall'Era M. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Curr Opin Rheumatol. 2011 Sep; 23(5):454-8.
  9. Yazdany J, Trupin L, Gansky SA, Dall'era M, Yelin EH, Criswell LA, Katz PP. Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2011 Aug; 63(8):1170-7.
  10. Dall'era M, Chakravarty EF. Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Curr Rheumatol Rep. 2011 Aug; 13(4):308-16.
  11. Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2011 Mar; 63(3):351-7.
  12. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, Hamacher NB, Lantry MM, Maurer M, Krejsa CM, Ellsworth JL, Pederson S, Elkon KB, Wener MH, Dall'Era M, Gross JA. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther. 2010; 12(2):R48.
  13. Dall'Era M, Wofsy D. Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through? Nat Rev Rheumatol. 2010 Mar; 6(3):124-5.
  14. Dall'Era M, Wofsy D. Biologic therapy for systemic lupus erythematosus. Discov Med. 2010 Jan; 9(44):20-3.
  15. Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis. Nat Rev Rheumatol. 2009 Jun; 5(6):348-51.
  16. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec; 56(12):4142-50.
  17. Gillis JZ, Dall'era M, Gross A, Yazdany J, Davis J. Six refractory lupus patients treated with rituximab: a case series. Arthritis Rheum. 2007 Apr 15; 57(3):538-42.
  18. Dall'Era M, Wofsy D. Clinical trial design in systemic lupus erythematosus. Curr Opin Rheumatol. 2006 Sep; 18(5):476-80.
  19. Dall'Era M, Davis JC. Systemic lupus erythematosus. How to manage, when to refer. Postgrad Med. 2003 Nov; 114(5):31-7, 40.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.